Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens.

CONCLUSIONS: Our meta-analysis indicates that CTLA-4 inhibitor is associated with a higher risk of colitis compared with PD-1/PD-L1 inhibitor, whether used as a monotherapy or combination immunotherapy. Importantly, the combination of PD-1/PD-L1 inhibitor with chemotherapy or targeted therapy may not increase the risk of colitis significantly compared to PD-1/PD-L1 inhibitor alone.
PMID: 32702598 [PubMed - as supplied by publisher]

Source: International Immunopharmacology - July 19, 2020 Category: Allergy & Immunology Authors: Yao J, Li M, Zhang H, Ge Y, Weygant N, An G Tags: Int Immunopharmacol Source Type: research